A newly identified strain of beneficial oral bacteria called Streptococcus salivarius G7 shows promise as a natural probiotic for preventing cavities and gum disease, according to research from UCLA and Dankook University. Unlike probiotics that originate in the gut, this bacterium naturally colonizes the human mouth and produces compounds that selectively suppress harmful pathogens without disrupting the broader oral microbiome.

How Does This Oral Probiotic Work Differently From Other Cavity Fighters?

The G7 strain operates through a mechanism that targets the root cause of tooth decay: acid production. When cavity-causing bacteria like Streptococcus mutans metabolize sugars, they produce acids that dissolve tooth enamel. Researchers found that S. mutans reduces the pH of the mouth to approximately 3.5 after 12 hours of growth, while the G7 strain maintains a much milder pH of about 5.38. This difference matters because tooth enamel begins to demineralize at around pH 5.5, meaning G7 is far less likely to contribute to decay and may help preserve a healthier oral environment.

Beyond low acid production, the G7 strain produces natural antibacterial compounds called bacteriocins that act like microscopic weapons against disease-causing bacteria. Laboratory experiments showed that substances produced by S. salivarius G7 significantly suppressed the growth of several dangerous oral pathogens, including Streptococcus mutans, Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitans, and Enterococcus faecalis. These bacteria are commonly linked to cavities, gum disease, periodontal infections, and root canal-related infections.

What Safety Testing Did Researchers Conduct Before Considering It for Human Use?

Safety is paramount for any probiotic intended for human consumption. The research team performed extensive genetic and laboratory testing to ensure the G7 strain could be safely developed as an oral probiotic. Here's what the safety evaluation included:

• Genetic Screening: Whole-genome sequencing confirmed that the strain did not contain virulence factors that might cause disease or transferable antibiotic-resistance genes that could contribute to the growing problem of antibiotic resistance.
• Antibiotic Susceptibility Testing: The bacterium was tested against multiple antibiotics commonly used in medicine, and resistance levels remained well below internationally accepted safety limits.
• Toxicity Assessments: Further tests demonstrated very low toxicity toward both oral cells and intestinal cells, with no production of D-lactate, a compound that can contribute to serious metabolic complications in vulnerable individuals.

In experiments using biofilms created from human saliva samples, researchers found that adding S. salivarius G7 significantly reduced populations of Streptococcus mutans while preserving overall beneficial bacterial communities. This finding highlights an increasingly important concept in oral health research: instead of simply killing bacteria, scientists are now seeking ways to restore microbial balance.

Why Is Microbiome Balance More Important Than Just Killing Bad Bacteria?

The human mouth contains more than 700 different microbial species that exist together in complex communities called biofilms. Oral diseases often emerge when this delicate ecosystem becomes unbalanced. Traditional approaches that indiscriminately kill bacteria can disrupt beneficial organisms and create conditions for resistant pathogens to flourish. The G7 strain appeared capable of supporting balance by selectively reducing harmful organisms without disrupting the wider oral ecosystem, offering a more sustainable approach to preventing dental disease.

This shift toward microbiome-centered thinking extends beyond oral health. Recent research on gut microbiota and cancer immunotherapy reveals how microbial metabolites produced by beneficial bacteria can influence immune function throughout the body. While the mechanisms differ, the principle is the same: maintaining a healthy microbial community may be more effective than attempting to eliminate specific pathogens.

Although larger human clinical studies will still be needed before G7 can be marketed as an oral probiotic, the evidence so far indicates that it is a highly promising candidate for future products aimed at improving dental and gum health. The strain successfully passed a wide range of safety evaluations, demonstrated low acid production, showed potent activity against disease-causing bacteria, and maintained the ability to help preserve a balanced oral microbiome.

The research was conducted by scientists from the Division of Regenerative and Reconstructive Sciences at UCLA's School of Dentistry and the Department of Oral Microbiology and Immunology at Dankook University's College of Dentistry in South Korea, with findings published in the peer-reviewed journal Microorganisms.